Tenax Therapeutics (NASDAQ:TENX) Stock Price Crosses Above 200 Day Moving Average – Time to Sell?

Tenax Therapeutics, Inc. (NASDAQ:TENX) passed above its two hundred day moving average during trading on Monday . The stock has a two hundred day moving average of $3.66 and traded as high as $5.09. Tenax Therapeutics shares last traded at $4.93, with a volume of 57,291 shares traded.

Wall Street Analysts Forecast Growth

TENX has been the topic of several recent analyst reports. Guggenheim initiated coverage on Tenax Therapeutics in a research note on Monday, October 14th. They set a “buy” rating and a $16.00 target price on the stock. Leerink Partners started coverage on Tenax Therapeutics in a research report on Thursday, October 24th. They set an “outperform” rating and a $16.00 price objective on the stock. William Blair began coverage on Tenax Therapeutics in a research report on Monday, September 30th. They issued an “outperform” rating for the company. Leerink Partnrs raised shares of Tenax Therapeutics to a “strong-buy” rating in a report on Thursday, October 24th. Finally, StockNews.com assumed coverage on shares of Tenax Therapeutics in a report on Thursday, September 26th. They set a “sell” rating for the company. One equities research analyst has rated the stock with a sell rating, four have issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $170.67.

Tenax Therapeutics Price Performance

The firm has a 50-day simple moving average of $3.95 and a 200-day simple moving average of $3.68.

Tenax Therapeutics (NASDAQ:TENX) last issued its quarterly earnings data on Tuesday, August 13th. The specialty pharmaceutical company reported ($1.83) earnings per share for the quarter, topping the consensus estimate of ($1.99) by $0.16. As a group, equities analysts anticipate that Tenax Therapeutics, Inc. will post -6.62 EPS for the current fiscal year.

Tenax Therapeutics Company Profile

Tenax Therapeutics, Inc develops and commercializes pharmaceutical products containing imatinib for the treatment of pulmonary arterial hypertension in the United States. The company develops TNX-101 (IV), TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia.